Related Experiment Video
Updated: May 3, 2026
06:57
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
Published on: September 18, 2016
8.4K
Therapeutic peptides in inflammatory bowel disease
Expert Opinion on Biological Therapy
|January 24, 2014
Summary
Biologic therapies, including tumor necrosis factor-alpha (TNF-a) blockers, have transformed inflammatory bowel disease (IBD) treatment. While effective, their optimal use and success with new targets like vedolizumab are still under investigation.
Area of Science:
- Gastroenterology and Immunology
- Pharmacological Research
Background:
- Current IBD therapies include mesalamine, corticosteroids, and immunosuppressants.
- Biologics, particularly tumor necrosis factor-alpha (TNF-a) antagonists, have revolutionized IBD treatment by targeting mucosal inflammation.
- Peptides, growth factors, and monoclonal antibodies are key therapeutic agents in IBD management.
Purpose of the Study:
- To review current evidence on biologic therapies for inflammatory bowel diseases.
- To assess the efficacy and safety of established and novel agents.
- To discuss limitations, biases, and clinical indications of these treatments.
Main Methods:
- Systematic review of controlled clinical trials and meta-analyses.
- Evaluation of safety data, including opportunistic infections and lymphoma risks.
- Analysis of heterogeneity in clinical guidelines and expert opinions.
Main Results:
- TNF blockers have significantly expanded treatment options for IBD.
- Reproducing the success of TNF blockers with other targets has been challenging.
- Vedolizumab, an anti-α4β7 integrin antibody, shows promise as a novel peptide therapy.
Conclusions:
- TNF blockers offer substantial benefits in IBD management.
- Debate continues regarding the extent of TNF blocker utilization.
- Further research is needed for novel agents like vedolizumab to establish their role in IBD therapy.
More Related Videos
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
34
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal...
34
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
01:25Inflammatory Bowel Disease III: Crohn's Disease
35
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
35
01:26Inflammatory Bowel Disease I: Introduction
42
Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows...
42
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755